88358-11-6Relevant articles and documents
Discovery of Adamantane Carboxamides as Ebola Virus Cell Entry and Glycoprotein Inhibitors
Plewe, Michael B.,Sokolova, Nadezda V.,Gantla, Vidyasagar Reddy,Brown, Eric R.,Naik, Shibani,Fetsko, Alexandra,Lorimer, Donald D.,Lorimer, Donald D.,Dranow, David M.,Dranow, David M.,Smutney, Hayden,Smutney, Hayden,Bullen, Jameson,Bullen, Jameson,Sidhu, Rana,Sidhu, Rana,Master, Arshil,Master, Arshil,Wang, Junru,Wang, Junru,Kallel, E. Adam,Zhang, Lihong,Kalveram, Birte,Freiberg, Alexander N.,Henkel, Greg,McCormack, Ken
supporting information, p. 1160 - 1167 (2020/05/14)
We identified and explored the structure-activity-relationship (SAR) of an adamantane carboxamide chemical series of Ebola virus (EBOV) inhibitors. Selected analogs exhibited half-maximal inhibitory concentrations (EC50 values) of ～10-15 nM in vesicular s
SPHINGOSINE KINASE INHIBITORS
-
Page/Page column 44, (2008/06/13)
The invention relates to substituted adamantane compounds, pharmaceutical compositions thereof, processes for their preparation, and methods for inhibiting sphingosine kinase and for treating or preventing hyperproliferative disease, inflammatory disease, or angiogenic disease.
